Bone loss in thyroid disease: Role of low TSH and high thyroid hormone

Annals of the New York Academy of Sciences

Volumn 1116, Issue , 2007, Pages 383-391

  Abe, Etsuko ^a   Sun, Li ^a   Mechanick, Jeffrey ^a   Iqbal, Jameel ^a   Yamoah, Kosj ^a   Baliram, Ramkumarie ^a   Arabi, Ario ^a   Moonga, Baljit S ^a   Davies, Terry F ^a   Zaidi, Mone ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bone remodeling; Osteoporosis; Thyroid receptor

Indexed keywords

RECOMBINANT THYROTROPIN; THYROID HORMONE; THYROTROPIN;

BONE DISEASE; CONFERENCE PAPER; GENETIC ASSOCIATION; HUMAN; NONHUMAN; OSTEOLYSIS; PATHOPHYSIOLOGY; THEOPHYLLINE BLOOD LEVEL; THYROID DISEASE; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL;

EID: 37249005803     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.062     Document Type: Conference Paper

References (62)

1. MURPHY, E. & G.R. WILLIAMS. 2004. The thyroid and the skeleton. Clin. Endocr. 61: 285-298.
2. DE MENIS, E et al. 1992. Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma. Horm. Res. 37: 217-220.
3. KISAKOL, G. et al. 2003. Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr. J. 50: 657-661.
4. FOLDES, J. et al. 1993. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clin. Endocr. 39: 521-527.
5. GURLEK, A. & O. GEDIK. 1999. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausalwomen. Thyroid 9: 539-543.
6. BASSETT, J.H. & G.R. WILLIAMS. 2003. The molecular actions of thyroid hormone in bone. Trends Endocrinol. Metab. 14: 356-353.
7. MARIANS, R.C. et al. 2002. Defining thyrotropin-dependent and -independent steps of thyroid hormone synthesis by using thyrotropin receptor-null mice. Proc. Natl. Acad. Sci. USA 99: 15776-15781.
8. ABE, E. et al. 2003. TSH is a negative regulator of skeletal remodeling. Cell 115: 151-162.
9. MUNDY, G.R. et al. 1976. Direct stimulation of bone resorption by thyroid hormones. J. Clin. Invest. 58: 529-534.
10. KANATANI, M. et al. 2004. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J. Cell. Physiol. 201: 17-25.
11. ALLAIN, T.J. et al. 1992. Tri-iodothyronine stimulates rat osteoclastic bone resorption by an indirect effect. J. Endocrinol. 133: 327-331.
12. BRITTO, J.M. et al. 1994. Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 134: 169-176.
13. KIM, C.H. et al. 1999. Thyroid hormone stimulates basal and interleukin (IL)-1-induced IL-6 production in human bone marrow stromal cells: a possible mediator of thyroid hormone-induced bone loss. J. Endocrinol. 160: 97-102.
14. ABU, E.O. et al. 2000. The localization of thyroid hormone receptor mRNAs in human bone. Thyroid 10: 287-293.
15. BASSETT, J.H. et al. 2007. Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol. Endocrinol. 21: 1095-1107.
16. BASSETT, J.H. et al. 2007. Thyroid status during skeletal development determines adult bone structure and mineralization. Mol. Endocrinol. May 8; [Epub ahead of print].
17. STEVENS, D.A. et al. 2000. Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. J. Bone Miner. Res. 15: 2431-2442.
18. BALLOCK, R.T. et al. 2000. Expression of cyclin-dependent kinase inhibitors in epiphyseal chondrocytes induced to terminally differentiate with thyroid hormone. Endocrinology 141: 4552-4557.
19. ISHIKAWA, Y. et al. 1998. Thyroid hormone inhibits growth and stimulates terminal differentiation of epiphyseal growth plate chondrocytes. J. Bone Miner. Res. 13: 1398-1411.
20. HIMENO, M. et al. 2002. Impaired vascular invasion of Cbfa1-deficient cartilage engrafted in the spleen. J. Bone Miner. Res. 17: 1297-1305.
21. TOH, S.H. et al. 1985. Effect of hyperthyroidism and its treatment on bone mineral content. Arch. Intern. Med. 145: 883-886.
22. FRANKLYN, J. et al. 1994. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clin. Endocrinol. (Oxf.) 41: 425-432.
23. DIAMOND, T. et al. 1994. Thyrotoxic bone disease inwomen: a potentially reversible disorder. Ann. Intern. Med. 120: 8-11.
24. CUMMINGS, S.R. et al. 1995. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med. 332: 767-773.
25. GRANT, D.J. 1995. Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin. Endocrinol. (Oxf.) 43: 339-345.
26. JODAR, E. et al. 1997. Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J. Clin. Endocrinol. Metab. 82: 1989-1994.
27. VESTERGAARD, P. et al. 2000. Fracture risk in patients treated for hyperthyroidism. Thyroid 10: 341-348.
28. SERRACLARA, A. et al. 2001. Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status. J. Clin. Densitom. 4: 249-255.
29. VESTERGAARD, P. & L. MOSEKILDE. 2003. Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid 13: 585-593.
30. IKEDA, F. et al. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114: 475-484.
31. SHEVDE, N.K. et al. 2000. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97: 7829-7834.
32. SRIVASTAVA, S. et al. 2001. Estrogen decreases osteoclast formation by downregulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276: 8836-8840.
33. KAWAIDA, R. et al. 2003. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J. Exp. Med. 197: 1029-1035.
34. HASE, H. et al. 2006. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone. Proc. Natl. Acad. Sci. USA 103: 12849-12854.
35. SIMSEK, G. et al. 2003. Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism. Chin. J. Physiol. 46: 181-186.
36. SAMPATH, T.K. et al. 2007. Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats. J. Bone Miner. Res. 22: 849-859.
37. MAZZIOTTI, G. et al. 2005. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J. Bone Miner. Res. 20: 480-486.
38. EPSTEIN, S. et al. 2003. Disorders associated with acute rapid and severe bone loss. J. Bone Miner. Res. 18: 2083-2094.
39. HEIJCKMANN, A.C. et al. 2005. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur. J. Endocrinol. 153: 23-29.
40. REVERTER, J. L et al. 2005. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr. Relat. Cancer 12: 973-981.
41. BAUER, D.C. et al. 2001. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 134: 561-568.
42. ALBERTI, L. et al. 2002. Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 87: 2549-2555.
43. KIM, D.J. et al. 2006. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin. Endocrinol. (Oxf.) 64: 86-90.
44. BAUER, D.C. et al. 2001. Study of Osteoporotic Fractures Research Group. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 134: 561-568.
45. SEELEY, D.G. et al. 1996. Predictors of ankle and foot fractures in older women. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11: 1347-1355.
46. KUNG, A.W. & S.S. YEUNG. 1996. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J. Clin. Endocrinol. Metab. 81: 1232-1236.
47. MCDERMOTT, M.T. et al. 1995. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer. Calcif. Tissue Int. 56: 521-525.
48. PIOLI, G. et al. 1992. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women. Acta. Endocrinol. (Copenh.) 126: 238-242.
49. RIBOT, C. et al. 1990. Bone mineral density and thyroid hormone therapy. Clin. Endocrinol. (Oxf.) 33: 143-153.
50. GUO, C.Y. et al. 1997. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin. Endocrinol. (Oxf.) 46: 301-307.
51. ROSS, D.S. 1993. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with subclinical hypothyroidism: a randomized, prospective study. Am. J. Med. 95: 385-388.
52. GARTON, M et al. 1994. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy. Clin. Endocrinol. (Oxf.) 41: 747-755.
53. FRAICHARD, A. et al. 1997. The T3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production. EMBO J. 16: 4412-4420.
54. WIKSTROM, et al. 1998. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J. 17: 455-461.
55. GAUTHIER, K. et al. 2001. Genetic analysis reveals different functions for the products of the thyroid hormone receptor alpha locus. Mol. Cell. Biol. 21: 4748-4760.
56. MACCHIA, P.E. et al. 2001. Increased sensitivity to thyroid hormone in mice with complete deficiency of thyroid hormone receptor alpha. Proc. Natl. Acad. Sci. USA 98: 349-354.
57. GAUTHIER, K. et al. 1999. Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development. EMBO J. 18: 623-631.
58. FORREST, D. et al. 1996. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function. EMBO J. 15: 3006-3015.
59. ABEL, E.D. et al. 1999. Divergent roles for thyroid hormone receptor beta isoforms in the endocrine axis and auditory system. J. Clin. Invest. 104: 291-300.
60. NG, et al. 2001. A thyroid hormone receptor that is required for the development of green cone photoreceptors. Nat. Genet. 27: 94-98.
61. KINDBLOM, J.M. et al. 2005. Increased adipogenesis in bone marrow but decreased bone mineral density in mice devoid of thyroid hormone receptors. Bone 36: 607-616.
62. GOTHE, S. et al. 1999. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev. 13: 1329-1341.